Interaksi Zaleplon

Tell your doctor if you have ever abused or been dependent on alcohol, prescription medicines or street drugs. (label Zaleplon, Peringatan kotak hitam)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

…modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which… (label Darunavir, Kontraindikasi)

…modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is contraindicated in patients receiving certain co-administered drugs for which altered plasma concentrations… (label Darunavir dan kobisistat, Kontraindikasi)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (label Difenoksilat dan atropin, Kontraindikasi)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

…Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment of pulmonary arterial hypertension Sedative/hypnotics: triazolam, orally administered midazolam Coadministration of GENVOYA is contraindicated with drugs that: Are highly dependent on CYP3A for clearance and for which… (label Elvitegravir, kobisistat, emtrisitabin, dan tenofovir, Kontraindikasi)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (label Fenelzin, Kontraindikasi)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

…Hypericum perforatum ) Lipid modifying agents: Lomitapide, lovastatin, simvastatin Non-nucleoside reverse transcriptase inhibitor: Delavirdine PDE5 inhibitor: Sildenafil (Revatio) (for treatment of pulmonary arterial hypertension) Sedative/hypnotics: Midazolam, triazolam Hypersensitivity to fosamprenavir calcium or amprenavir (e.g., Stevens-Johnson syndrome). (label Fosamprenavir, Kontraindikasi)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (label Ketokonazol, Kontraindikasi)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (label Levosetirizin, Peringatan dan perhatian)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

…Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension Sedative/Hypnotics: triazolam, orally administered midazolam KALETRA is contraindicated with drugs that are potent CYP3A inducers where significantly reduced lopinavir plasma concentrations… (label Lopinavir dan ritonavir, Kontraindikasi)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (label Nalmefen, Peringatan dan perhatian)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

…(selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin receptor 1A agonist/serotonin receptor 2A antagonist: flibanserin • Vasopressin receptor antagonists: tolvaptan ➢ Drugs that… (label Nirmatrelvir dan ritonavir, Kontraindikasi)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (label Olopatadin, Peringatan dan perhatian)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (label Olopatadin dan mometason, Peringatan dan perhatian)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (label Ritonavir, Peringatan kotak hitam)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (label Setirizin, Peringatan dan perhatian)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (label Siprofloksasin, Interaksi obat)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (label Zaleplon, Peringatan)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (label Alopurinol, Peringatan dan perhatian)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (label Aminofilin, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (label Biktegravir, emtrisitabin, dan tenofovir alafenamid, Interaksi obat)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Use with CNS depressants may result in an additive or potentiating effect. (label Brimonidin, Interaksi obat)

Use with CNS depressants may result in an additive or potentiating effect. (label Brimonidin dan timolol, Interaksi obat)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (label Bupivakain, Peringatan dan perhatian)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (label Bupivakain dan epinefrin, Peringatan dan perhatian)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (label Buspiron, Interaksi obat)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (label Deutetrabenazin, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Post-marketing reports have shown that complex sleep behaviors may occur with zaleplon alone at recommended dosages, with or without the concomitant use of alcohol or other central nervous system (CNS) depressants. (label Zaleplon, Peringatan)

The magnitude of interaction with multiple doses of erythromycin is unknown. (label Zaleplon, Interaksi obat)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug. (label Zaleplon, Interaksi obat)

There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug. (label Zaleplon, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (label Lidokain dan epinefrin, Peringatan dan perhatian)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (label Metirosin, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (label Nalokson, Peringatan dan perhatian)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug. (label Zaleplon, Interaksi obat)

Paroxetine: Coadministration of a single dose of zaleplon 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance. (label Zaleplon, Interaksi obat)

Post-marketing reports have shown that complex sleep behaviors may occur with zaleplon alone at recommended dosages, with or without the concomitant use of alcohol or other central nervous system (CNS) depressants. (label Zaleplon, Peringatan)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Concomitant administration of zaleplon (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean C max and AUC of zaleplon. (label Zaleplon, Interaksi obat)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (label Zaleplon, Interaksi obat)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (label Teofilin, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (label Trimetobenzamid, Peringatan dan perhatian)

Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine. (label Zaleplon, Interaksi obat)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (label Zaleplon, Interaksi obat)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (label Dekstroamfetamin, Interaksi obat)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (label Doksapram, Peringatan)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (label Epoetin alfa, Peringatan dan perhatian)

…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (label Prazosin, Interaksi obat)

Drugs with a Narrow Therapeutic Index Digoxin: Zaleplon (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days). (label Zaleplon, Interaksi obat)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (label Montelukast, Interaksi obat)

Warfarin: Multiple oral doses of zaleplon (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin. (label Zaleplon, Interaksi obat)